AMRX vs VTRS
AMRX: Amneal Pharmaceuticals is a diversified biopharma company providing a broad range of essential, affordable generic and specialty medicines, alongside pharmaceutical distribution services. VTRS: A global pharmaceutical giant supplying over 1 billion patients annually with generics, branded medicines, and an expanding innovative pipeline across more than 165 countries.
Side-by-side fundamentals
| Metric | AMRX | VTRS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $17.75 | $17.01 | |
| Market cap as of 2026-07-23 | $5.7B | $20.0B | |
| P/E as of 2026-07-23 | 46.42 | n/a | |
| PEG as of 2026-07-23 | 2.57 | 1.44 | VTRS lower |
| Net margin as of 2026-07-23 | +4.0% | -2.0% | AMRX higher |
| Gross margin as of 2026-07-23 | +38.7% | +39.8% | VTRS higher |
| Operating margin as of 2026-07-23 | +14.3% | +0.3% | AMRX higher |
| ROE as of 2026-07-23 | -34.9% | -2.0% | VTRS higher |
| ROA as of 2026-07-23 | +3.4% | -0.8% | AMRX higher |
| Debt / equity as of 2026-07-23 | 136.58 | 0.98 | VTRS lower |
| Revenue growth (YoY) as of 2026-07-23 | +7.6% | +1.6% | AMRX higher |
| Revenue CAGR (3y) SEC XBRL | +10.9% | -4.2% | AMRX higher |
| Dividend yield as of 2026-07-23 | n/a | +2.8% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 1.26 | 0.91 | |
| 1-year return as of 2026-07-22 close | +123.0% | +84.1% | AMRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.